Top Markets
Coin of the day
Devonian Health Group Inc. Devonian Health Group Inc.

Devonian Health Group Inc.

DVHGF
Rang in Aktien #29818
Devonian Health Group Inc. specializes in the creation of botanical-based... Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
Aktienkurs
$7.00
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$19.47M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-35.19%
Land
CA
Handel Devonian Health Group Inc. (DVHGF)

Kategorie

Dividendenhistorie für Devonian Health Group Inc. (DVHGF)
Devonian Health Group Inc. (Aktienkürzel: DVHGF) zahlte insgesamt 0 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: 0.00
Dividendenrendite (TTM): 0
Dividendenzahlungen für Devonian Health Group Inc. (DVHGF) von 2026 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
Nicht genügend Daten für die angegebenen Daten.
Liste aller Dividendenzahlungen
Jahr Dividende ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Dividendenzahlungen Land
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH
0.00%
KR